Denison Mines announces $250 million convertible notes offering
In recent transactions involving Akero Therapeutics, Inc. (NASDAQ:AKRO), which has seen its stock decline nearly 13% over the past week despite a strong 59% gain over the last year, Chief Scientific Officer Rolph Timothy executed a series of stock sales totaling $224,261. According to InvestingPro data, the company appears undervalued at its current market capitalization of $2.74 billion. The sales occurred on April 7, 2025, with prices ranging from $35.356 to $37.915 per share. These transactions were part of a pre-established trading plan under Rule 10b5-1, adopted by Timothy in August 2024.
In addition to the sales, Timothy also exercised stock options to acquire 6,250 shares at a price of $21.1 each, resulting in a total acquisition value of $131,875. Following these transactions, Timothy holds 169,721 shares of Akero Therapeutics.
In other recent news, Akero Therapeutics has seen a series of analyst upgrades following promising trial results for its leading drug candidate, efruxifermin (EFX), aimed at treating non-alcoholic steatohepatitis (NASH) and metabolic-associated steatohepatitis (MASH). Citi analysts raised their price target for Akero Therapeutics to $80, highlighting the positive 96-week SYMMETRY data for EFX in patients with compensated cirrhosis. Similarly, Jefferies increased their target to $75, citing a significant market opportunity for Akero in the NASH sector. Canaccord Genuity also adjusted its target to $73, emphasizing the strong fibrosis improvement shown in recent trials. H.C. Wainwright updated its price target to $75, reflecting the potential market value of EFX for patients with MASH and F2/F3 fibrosis. These developments suggest increased confidence in Akero's potential to capture a substantial share of the market, with multiple firms maintaining a Buy rating on the stock. The ongoing advancements in Akero's clinical trials have sparked interest from larger pharmaceutical companies, positioning it as a potential acquisition target. Investors are closely monitoring the potential for accelerated FDA approval, which could further enhance Akero's market prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.